The Michelson Prizes for Human Immunology and Vaccine Research will award $150,000 prizes to two young investigators under the age of 35 that are applying innovative research concepts and disruptive technologies to significantly advance the development of future vaccines and immunotherapies for major global diseases.
A rigorous and competitive global search will be undertaken to identify the most innovative projects by young scientists across a broad spectrum of scientific fields. To be considered, applicants need to show how they are going beyond conventional approaches in their field and clearly articulate how their contribution will make a lasting impact on human immunology and vaccine research. Early career scientists across a wide array of disciplines, including biomedical, bioengineering and computer science fields, are encouraged to apply.
Prizes will be awarded in June 2018 as part of a scientific conference on the Convergence of Human Immunology and Vaccine Research hosted at The Michelson Center for Convergent Bioscience at the University of Southern California. Proposals will be reviewed and winners selected by a distinguished committee of internationally-recognized, independent scientists.
The Michelson Medical Research Foundation together with the Human Vaccines Project are establishing The Michelson Prizes for Human Immunology and Vaccine Research with the ultimate goal of broadening understanding of the immune system to give the scientific community new tools to prevent and control disease, potentially saving millions of lives around the world.
Pre-application deadline is Feb. 12, 2018.
Email MichelsonPrizes@HumanVaccinesProject.org with questions.
This is considered an out of date browser. This website has been developed with modern browsers in mind to allow it to display at its best in a wide variety of viewing situations - including mobile viewing. But we haven't supported older browsers like IE8. Please upgrade to the latest version of Internet Explorer - or try Mozilla Firefox or Google Chrome. Both are excellent browsers.